Literature DB >> 11193890

9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice.

V Knight1, E S Kleinerman, J C Waldrep, B C Giovanella, B E Gilbert, N V Koshkina.   

Abstract

The purpose of this study was to test the anticancer properties of the water-insoluble derivative of camptothecin, 9-nitrocamptothecin (9NC), administered in a liposome formulation (L-9NC) in aerosol to mice with subcutaneous xenografts of three human cancers and in mice with murine melanoma and human osteosarcoma pulmonary metastases. The drug was formulated with dilauroylphosphatidylcholine and nebulized in particle sizes of 1.2-1.6 microns mass median aerodynamic diameter and a geometric standard deviation of 2.0. The aerosol was generated with the nebulizer flowing at 10 l/min and delivered to mice in sealed plastic cages or in a nose-only exposure chamber. Aerosol was administered for 15 min to 2 hr daily, delivering deposited doses in the respiratory tract of 8.1-306.7 micrograms of 9NC/kg. With subcutaneous tumors, growth was greatly inhibited or tumors were undetectable after several weeks of treatment. We also showed that oral dosage with L-9NC had no detectable effect on cancer growth, and thus the benefit from aerosol treatment was due to pulmonary deposition and not the larger fraction of drug deposited in the nose of mice during aerosol treatment which is promptly swallowed. Intramuscular L-9NC in slightly larger doses than given in the aerosol had detectable anticancer activity, but it was significantly less than in mice receiving the drug by aerosol. With metastatic pulmonary cancers, treated animals showed highly significantly less cancer growth than control animals. L-9NC aerosol showed a major therapeutic benefit in the treatment of subcutaneous human cancer xenografts in nude mice, suggesting that cancers at systemic sites might be responsive to this treatment. In addition, the strong anticancer effect of L-9NC aerosol on pulmonary metastases offers a therapeutic approach for treatment of pulmonary cancers. Thus, L-9NC aerosol may have applicability in the treatment of cancers throughout the body.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11193890     DOI: 10.1111/j.1749-6632.2000.tb07033.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  5 in total

Review 1.  Camptothecin delivery methods.

Authors:  A Hatefi; B Amsden
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

Review 2.  Camptothecins: a review of their chemotherapeutic potential.

Authors:  Hulya Ulukan; Peter W Swaan
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis.

Authors:  Sergei R Guma; Dean A Lee; Ling Yu; Nancy Gordon; Dennis Hughes; John Stewart; Wei Lien Wang; Eugenie S Kleinerman
Journal:  Pediatr Blood Cancer       Date:  2013-10-18       Impact factor: 3.167

4.  Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation.

Authors:  Euan Ramsay; Jehan Alnajim; Malathi Anantha; Aman Taggar; Anitha Thomas; Katarina Edwards; Göran Karlsson; Murray Webb; Marcel Bally
Journal:  Pharm Res       Date:  2006-10-25       Impact factor: 4.580

Review 5.  Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer Applications.

Authors:  Mindaugas Rudokas; Mohammad Najlah; Mohamed Albed Alhnan; Abdelbary Elhissi
Journal:  Med Princ Pract       Date:  2016-03-02       Impact factor: 1.927

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.